.png){kind=icon}
返回
ELUCIDATE Trial: A Single-Center Randomized Controlled Study
.png){kind=icon}
OA
AI
DOI：10.1161/JAHA.123.033832.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Background: Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, is an epochal oral antidiabetic drug that improves cardiorenal outcomes. However, the effect of early dapagliflozin intervention on left ventricular (LV) remodeling in patients with type 2 diabetes free from cardiovascular disease remains unclear. Methods and Results: The ELUCIDATE trial was a prospective, open-label, randomized, active-controlled study that enrolled 76 patients with asymptomatic type 2 diabetes with LV ejection fraction >= 50%, randomized to the dapagliflozin 10 mg/day add-on or standard-of-care group. Speckle-tracking echocardiography-based measurements of the cardiac global longitudinal strain were performed at baseline and 24 weeks after treatment initiation. Patients who received dapagliflozin had a greater reduction in LV dimension (1.68 mm [95% CI, 0.53-2.84]; P=0.005), LV end-systolic volume (5.51 mL [95% CI, 0.86-10.17]; P=0.021), and LV mass index (4.25 g/m(2.7) [95% CI, 2.42-6.09]; P<0.0001) compared with standard of care in absolute mean differences. Dapagliflozin add-on therapy led to a significant LV global longitudinal strain increment (0.74% [95% CI, 1.00-0.49]; P<0.0001) and improved LV systolic and early diastolic strain rates (0.27/s [95% CI, 0.17-0.60]; and 0.11/s [95% CI, 0.06-0.16], respectively; both P<0.0001) but not in global circumferential strain. No significant changes were found in insulin resistance, NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels, or other biomarkers at 6 months after the dapagliflozin administration. Conclusions: Dapagliflozin add-on therapy could lead to more favorable cardiac remodeling accompanied by enhanced cardiac mechanical function among patients with asymptomatic type 2 diabetes. Our findings provide evidence of the efficacy of dapagliflozin use for the primary prevention of diabetic cardiomyopathy.
Keyword:
clinical trial
dapagliflozin
echocardiography
sodium-glucose cotransporter 2 inhibitors
type 2 diabetes
ventricular remodeling
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
5.3
论文数:
1.1W
被引数:
4.5W
机构
引用论文
Improving the Characterization of Stage A and B Heart Failure by Adding Global Longitudinal StrainOAAI
OAAI分享收藏Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)2022年2型糖尿病高血糖的管理。美国糖尿病协会 (ADA) 和欧洲糖尿病研究协会 (EASD) 的共识报告.png)
DIABETES CARE
OAAI
DIABETES CAREIF16.6
OAAI分享收藏Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease The Atherosclerosis Risk In the Community Studyjacc heart failureOAAI
jacc heart failureIF8.4
OAAI分享收藏Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)CIRCULATIONOAAI
CIRCULATIONIF38.6
OAAI分享收藏Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction A Substudy of the Empire HF Randomized Clinical TrialJAMA CARDIOLOGYOAAI
JAMA CARDIOLOGYIF14.1
OAAI分享收藏Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023DIABETES CAREOAAI
DIABETES CAREIF16.6
OAAI分享收藏Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction达格列净治疗轻度降低或保留射血分数的心力衰竭OAAI
OAAI分享收藏
查看更多内容